The company is on the cutting edge of the growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide.
Predictive Oncology’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug and tumor type combinations for subsequent in-vitro testing.
According to the drug development firm, the move will further strengthen its commitment to scientific discovery and growth potential.
The news comes on the heels of Predictive Oncology’s recent expansion to nearly 20,000 feet of commercial space in the Lawrenceville section of Pittsburgh.
Raymond Vennare, CEO and chairman of the board at Predictive Oncology, said: “This move reinforces the company’s commitment to growth, solidifying our footprint and expanding the laboratory and center for artificial intelligence in Pittsburgh.”
“Our Company not only employs some of the world’s leading scientists in their respective fields, but has access to a critical mass of talent, many of whom were drawn to the region by Carnegie Mellon University, the University of Pittsburgh and UPMC Medical Center.”
Dr. Arlette Uihlein, SVP of translational medicine and drug discovery at Predictive Oncology, added: “Pittsburgh has long been a catalyst for innovation in the life sciences from Precision Therapeutics to the McGowen Institute for Regenerative Medicine and the Pittsburgh Tissue Engineering Initiative. Predictive Oncology stands on the shoulders of that kind of ingenuity and inventiveness. With this move, our facility in Pittsburgh has now become the epicenter of our company’s artificial intelligence and clinical operations.”